Race Oncology Limited

Equities

RAC

AU000000RAC3

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 08:16:07 04/06/2024 am IST			5-day change	1st Jan Change
1.595 ^AUD	-3.33%		+13.52%	+89.88%

26/03	Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	MT
18/03	Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	CI

Race Oncology poised for observational heart protection breast cancer trial

March 14, 2023 at 10:24 pm IST

(via NewsDirect)

Race Oncology Ltd (ASX:RAC) CEO Damian Clarke-Bruce tells Proactive that they will shortly start assessing the cardiovascular-protective properties of Zantrene® (bisantrene) treatment in the observational stage of a Phase 1/2b clinical trial in breast cancer patients treated with doxorubicin and cyclophosphamide with at least two cardiovascular risk factors. Resolutum Global, Beyond Drug Development and NSW Regional Biospecimen & Research Services have been appointed to support the clinical program.

Contact Details

Gregg Castano

+1 203-762-5649

gregg.castano@newsdirect.com

Latest news about Race Oncology Limited

Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	26/03	MT
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	18/03	CI
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment	06/03	MT
Race Oncology Widens Loss in Fiscal H1	28/02	MT
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Race Oncology Names CEO; Shares Jump 5%	22/11	MT
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer	22/11	CI
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	05/23/05	MT
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index	18/23/18	CI
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Race Oncology Limited Announces Board Changes	22/23/22	CI
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	13/23/13	MT
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	12/23/12	CI
Race Oncology Signs Manufacturing Deal for Intravenous Formulation; Shares Fall 4%	12/23/12	MT
Race Oncology Limited Executes Global License Agreement with City of Hope to Access FTO IP	11/23/11	CI
Race Oncology Secures License Deal for Cancer Research Intellectual Property	10/23/10	MT
Race Oncology Limited Announces Board Changes	29/23/29	CI
Tranche Update on Race Oncology Limited's Equity Buyback Plan announced on June 9, 2022.	22/23/22	CI
Race Oncology Limited's Equity Buyback announced on June 9, 2022, has closed with 634,881 shares, representing 0.40% for AUD 1.28 million.	22/23/22	CI
Race Oncology Names Chief Medical Officer	09/23/09	MT
Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023	09/23/09	CI
Race Oncology Releases Detailed Commercial Assessment for Zantrene's Market Potential; Shares Jump 7%	14/23/14	MT
Race Oncology Receives AU$1.5 Million R&D Tax Rebate	27/23/27	MT
Race Oncology Scientific Chief to Step Down; Shares Fall 10%	24/23/24	MT
Race Oncology Limited Announces Management Changes	24/23/24	CI

Chart Race Oncology Limited

Duration

Period

More charts

Company Profile

Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Sector

Biotechnology & Medical Research

Calendar

23/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RACE ONCOLOGY LIMITED	+89.88%	167M
MODERNA, INC.	+48.64%	54.63B
IQVIA HOLDINGS INC.	-6.44%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.28%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.40%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.64%	12.21B
BIO-TECHNE CORPORATION	+0.96%	12.16B
MEDPACE HOLDINGS, INC.	+27.04%	11.94B

Other Biotechnology & Medical Research

Race Oncology Limited

Equities

RAC

AU000000RAC3

Biotechnology & Medical Research

Race Oncology poised for observational heart protection breast cancer trial

Contact Details

Latest news about Race Oncology Limited

Chart Race Oncology Limited

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research